Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

Abstract Background The cannabigerol derivative VCE-003.2, which has activity at the peroxisome proliferator-activated receptor-γ has afforded neuroprotection in experimental models of Parkinson’s disease (PD) based on mitochondrial dysfunction (6-hydroxydopamine-lesioned mice) and neuroinflammation...

Full description

Bibliographic Details
Main Authors: Sonia Burgaz, Elisa Navarro, Santiago Rodríguez-Carreiro, Carmen Navarrete, Martin Garrido-Rodríguez, Isabel Lastres-Becker, Julia Chocarro, José L. Lanciego, Eduardo Muñoz, Javier Fernández-Ruiz
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Behavioral and Brain Functions
Subjects:
VCE-003.2
Parkinson’s disease
alpha-synuclein 
Cannabinoids
PPAR-γ
Online Access:https://doi.org/10.1186/s12993-024-00256-9

Internet

https://doi.org/10.1186/s12993-024-00256-9

Similar Items